$0.17 EPS Expected for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) This Quarter

Equities research analysts predict that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating) will post earnings per share of $0.17 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Catalyst Pharmaceuticals’ earnings, with estimates ranging from $0.16 to $0.19. Catalyst Pharmaceuticals posted earnings of $0.16 per share in the same quarter last year, which would indicate a positive year over year growth rate of 6.3%. The firm is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Catalyst Pharmaceuticals will report full year earnings of $0.67 per share for the current financial year, with EPS estimates ranging from $0.64 to $0.74. For the next year, analysts anticipate that the business will post earnings of $0.80 per share, with EPS estimates ranging from $0.70 to $0.90. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Rating) last released its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.02). Catalyst Pharmaceuticals had a return on equity of 23.95% and a net margin of 29.31%. During the same period last year, the business posted $0.09 EPS.

CPRX has been the subject of several research analyst reports. Piper Sandler increased their price objective on Catalyst Pharmaceuticals from $8.00 to $8.75 in a research report on Thursday, March 17th. Truist Financial reaffirmed a “buy” rating and issued a $12.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, March 18th. HC Wainwright raised their price objective on Catalyst Pharmaceuticals from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, February 7th. Finally, StockNews.com downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 12th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $9.75.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Arrowstreet Capital Limited Partnership purchased a new position in Catalyst Pharmaceuticals in the third quarter valued at approximately $163,000. USA Financial Portformulas Corp acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $196,000. Tanaka Capital Management Inc. grew its position in shares of Catalyst Pharmaceuticals by 17.3% during the 3rd quarter. Tanaka Capital Management Inc. now owns 203,079 shares of the biopharmaceutical company’s stock valued at $1,076,000 after buying an additional 30,000 shares during the last quarter. E Fund Management Co. Ltd. bought a new position in Catalyst Pharmaceuticals in the third quarter worth about $57,000. Finally, Metropolitan Life Insurance Co NY boosted its position in Catalyst Pharmaceuticals by 18.4% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 26,407 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 4,109 shares during the period. 64.28% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ CPRX opened at $7.17 on Wednesday. The business’s 50 day moving average is $7.85 and its two-hundred day moving average is $7.19. The stock has a market capitalization of $736.93 million, a price-to-earnings ratio of 17.07 and a beta of 1.29. Catalyst Pharmaceuticals has a 12-month low of $4.81 and a 12-month high of $8.65.

About Catalyst Pharmaceuticals (Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Featured Stories

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.